252 related articles for article (PubMed ID: 30745517)
1. [Personalized medicine for oral molecular-targeted anticancer drugs].
Miura M
Nihon Yakurigaku Zasshi; 2019; 153(2):73-78. PubMed ID: 30745517
[TBL] [Abstract][Full Text] [Related]
2. Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine.
Groenland SL; Mathijssen RHJ; Beijnen JH; Huitema ADR; Steeghs N
Eur J Clin Pharmacol; 2019 Sep; 75(9):1309-1318. PubMed ID: 31175385
[TBL] [Abstract][Full Text] [Related]
3. Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies.
Widmer N; Bardin C; Chatelut E; Paci A; Beijnen J; Levêque D; Veal G; Astier A
Eur J Cancer; 2014 Aug; 50(12):2020-36. PubMed ID: 24928190
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic drug monitoring of targeted anticancer therapy.
Decosterd LA; Widmer N; Zaman K; Cardoso E; Buclin T; Csajka C
Biomark Med; 2015; 9(9):887-93. PubMed ID: 26333311
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic drug monitoring of oral targeted antineoplastic drugs.
Mueller-Schoell A; Groenland SL; Scherf-Clavel O; van Dyk M; Huisinga W; Michelet R; Jaehde U; Steeghs N; Huitema ADR; Kloft C
Eur J Clin Pharmacol; 2021 Apr; 77(4):441-464. PubMed ID: 33165648
[TBL] [Abstract][Full Text] [Related]
6. Effect of Adherence on Pharmacokinetic/Pharmacodynamic Relationships of Oral Targeted Anticancer Drugs.
Cardoso E; Csajka C; Schneider MP; Widmer N
Clin Pharmacokinet; 2018 Jan; 57(1):1-6. PubMed ID: 28634655
[TBL] [Abstract][Full Text] [Related]
7. [Toward Personalized Cancer Therapy with Oral Molecular-targeted Agents].
Yamaguchi H; Takasaki S; Kikuchi M; Kawasaki Y; Arai Y; Mano N
Yakugaku Zasshi; 2019; 139(6):911-915. PubMed ID: 31155535
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
Haouala A; Zanolari B; Rochat B; Montemurro M; Zaman K; Duchosal MA; Ris HB; Leyvraz S; Widmer N; Decosterd LA
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jul; 877(22):1982-96. PubMed ID: 19505856
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic drug monitoring in cancer--are we missing a trick?
Bardin C; Veal G; Paci A; Chatelut E; Astier A; Levêque D; Widmer N; Beijnen J
Eur J Cancer; 2014 Aug; 50(12):2005-9. PubMed ID: 24878063
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological Profile and Pharmacogenomics of Anti-Cancer Drugs Used for Targeted Therapy.
Di Francia R; De Monaco A; Saggese M; Iaccarino G; Crisci S; Frigeri F; De Filippi R; Berretta M; Pinto A
Curr Cancer Drug Targets; 2018; 18(5):499-511. PubMed ID: 28183252
[TBL] [Abstract][Full Text] [Related]
11. Review of therapeutic drug monitoring of anticancer drugs part 1--cytotoxics.
Paci A; Veal G; Bardin C; Levêque D; Widmer N; Beijnen J; Astier A; Chatelut E
Eur J Cancer; 2014 Aug; 50(12):2010-9. PubMed ID: 24889915
[TBL] [Abstract][Full Text] [Related]
12. Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial.
Gotta V; Widmer N; Decosterd LA; Chalandon Y; Heim D; Gregor M; Benz R; Leoncini-Franscini L; Baerlocher GM; Duchosal MA; Csajka C; Buclin T
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1307-19. PubMed ID: 25297989
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Drug Monitoring of Oral Anticancer Drugs: The Dutch Pharmacology Oncology Group-Therapeutic Drug Monitoring Protocol for a Prospective Study.
Groenland SL; van Eerden RAG; Verheijen RB; Koolen SLW; Moes DJAR; Desar IME; Reyners AKL; Gelderblom HJ; van Erp NP; Mathijssen RHJ; Huitema ADR; Steeghs N
Ther Drug Monit; 2019 Oct; 41(5):561-567. PubMed ID: 31568233
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacokinetics and therapeutic drug monitoring of anticancer agents].
Marquet P; Rousseau A
Bull Cancer; 2008 Oct; 95(10):903-9. PubMed ID: 19004719
[TBL] [Abstract][Full Text] [Related]
15. Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs.
Rousseau A; Marquet P
Fundam Clin Pharmacol; 2002 Aug; 16(4):253-62. PubMed ID: 12570013
[TBL] [Abstract][Full Text] [Related]
16. Dose Individualization of Oral Multi-Kinase Inhibitors for the Implementation of Therapeutic Drug Monitoring.
Noda S; Morita SY; Terada T
Biol Pharm Bull; 2022; 45(7):814-823. PubMed ID: 35786588
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Drug Monitoring of Targeted Anticancer Protein Kinase Inhibitors in Routine Clinical Use: A Critical Review.
Cardoso E; Guidi M; Blanchet B; Schneider MP; Decosterd LA; Buclin T; Csajka C; Widmer N
Ther Drug Monit; 2020 Feb; 42(1):33-44. PubMed ID: 31479043
[TBL] [Abstract][Full Text] [Related]
18. Imatinib, sunitinib and pazopanib: From flat-fixed dosing towards a pharmacokinetically guided personalized dose.
Westerdijk K; Desar IME; Steeghs N; van der Graaf WTA; van Erp NP;
Br J Clin Pharmacol; 2020 Feb; 86(2):258-273. PubMed ID: 31782166
[TBL] [Abstract][Full Text] [Related]
19. Making TDM work to optimize cancer chemotherapy: a multidisciplinary team approach.
Hon YY; Evans WE
Clin Chem; 1998 Feb; 44(2):388-400. PubMed ID: 9474050
[TBL] [Abstract][Full Text] [Related]
20. Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets.
Yu H; Steeghs N; Nijenhuis CM; Schellens JH; Beijnen JH; Huitema AD
Clin Pharmacokinet; 2014 Apr; 53(4):305-25. PubMed ID: 24566736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]